Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Assets: 2017-2025

Historic Assets for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $175.5 million.

  • Aclaris Therapeutics' Assets fell 3.76% to $175.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $175.5 million, marking a year-over-year decrease of 3.76%. This contributed to the annual value of $220.3 million for FY2024, which is 11.61% up from last year.
  • As of Q3 2025, Aclaris Therapeutics' Assets stood at $175.5 million, which was down 7.20% from $189.1 million recorded in Q2 2025.
  • Aclaris Therapeutics' 5-year Assets high stood at $288.0 million for Q2 2021, and its period low was $161.1 million during Q2 2024.
  • Over the past 3 years, Aclaris Therapeutics' median Assets value was $197.4 million (recorded in 2023), while the average stood at $198.3 million.
  • As far as peak fluctuations go, Aclaris Therapeutics' Assets surged by 266.46% in 2021, and later crashed by 31.65% in 2024.
  • Over the past 5 years, Aclaris Therapeutics' Assets (Quarterly) stood at $251.2 million in 2021, then climbed by 1.35% to $254.6 million in 2022, then declined by 22.46% to $197.4 million in 2023, then rose by 11.61% to $220.3 million in 2024, then fell by 3.76% to $175.5 million in 2025.
  • Its Assets stands at $175.5 million for Q3 2025, versus $189.1 million for Q2 2025 and $198.1 million for Q1 2025.